Related Experiment Video
Updated: Jul 23, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
Combined behavioral and pharmacological treatments for smoking cessation
1Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. Mstitzer@jhmi.edu
Abstract:
Combined behavioral and pharmacological therapies appear to be the best approach for treating tobacco dependence. Because these therapies operate by different mechanisms, complementary and potentially additive effects may be expected. This paper focuses on nicotine replacement therapies (NRT) combined with supportive counseling because they are the most widely used and intensively researched treatment methods. Nicotine replacement medications and counseling appear to produce additive or less than additive effects when combined. Additive effects of combined therapies are generally apparent in the number of smokers who survive the first few weeks without smoking, but may disappear at longer-term follow-up. Because any smoking in the first two post-quit weeks is strongly associated with poor treatment outcome, reduced incidence of early smoking re-exposure appears to be important for improving long-term smoking cessation. Mechanisms underlying additive effects need further clarification. What are the independent and interactive roles of compliance with medication and with behavior change prescriptions, of pharmacological withdrawal suppression, of relapse prevention skills training, and of social support provided by counseling? Given the prevalence and importance of post-quit smoking relapses, can anything be done to further reduce incidence or to counteract their deleterious effects? Do any existing treatments slow relapse? If not, how can this be accomplished? Effective treatments now exist, but these cannot have an impact unless they are used; we need to know what methods can effectively enhance use.
More Related Videos
Related Concept Videos
Drug Dependence
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Antidepressant Drugs: MAOIs and Other Agents
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...

